MRI screening for breast cancer in women with a familial or genetic predisposition

Imaging Decisions MRI

Volumn 9, Issue 2, 2005, Pages 11-18

  Kriege, Mieke ^a   Brekelmans, C T M ^a   Klijn, J G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BRCA 1 2; Breast cancer; Familial risk; Magnetic resonance imaging; Review; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

BREAST CANCER; BREAST EXAMINATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; ENDOMETRIUM CANCER; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; INTERMETHOD COMPARISON; MAMMOGRAPHY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOLOGY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

EID: 27744471732     PISSN: 14333317     EISSN: 16170830     Source Type: Journal    
DOI: 10.1111/j.1617-0830.2005.00041.x     Document Type: Review

References (82)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl. 8): 4-66.
2. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
3. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
4. The GHEK2-breast cancer consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59.
5. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-2347.
6. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist 2003; 8: 466-473.
7. Peto J. Breast cancer susceptibility - a new look at an old model. Cancer Cell 2002; 1: 411-412.
8. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
9. Peto J, Gollins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91: 943-949.
10. Easton DF, Ford D, Bishop DT, Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 56: 265-271.
11. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457-1462.
12. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
13. Euhus DM. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J 2001; 7: 224-232.
14. Meijers-Heijboer H, van Geel AN, van Putten WLJ et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
15. Hartmann LG, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-1637.
16. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
17. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
18. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
19. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
20. King MG, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-2256.
21. Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 1876-1881.
22. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971; 215: 1777-1785.
23. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 2004; 42: 793-806, v.
24. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-919.
25. Walter SD. Mammographic screening: case-control studies. Ann Oncol 2003; 14: 1190-1192.
26. Swedish Cancer Society and the Swedish National Board of Health and Welfare. Report of the Organizing Committee and Collaborators, Falun Meeting, Falun, Sweden (21 and 22 March, 1996). Breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996; 68: 693-699.
27. DeKoning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995; 87: 1217-1223.
28. Tabar L, Fagerberg G, Chen HH et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995; 75: 2507-2517.
29. Mandelson MT, Oestreicher N, Porter PL et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92: 1081-1087.
30. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225: 165-175.
31. Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. Cancer 1993; 71: 3547-3551.
32. Otto SJ, Fracheboud J, Looman CW et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003; 361: 1411-1417.
33. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
34. Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, De Koning HJ. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004; 91: 242-247.
35. McDonald S, Saslow D, Alciati MH. Performance and reporting of clinical breast examination: a review of the literature. CA Cancer J Clin 2004; 54: 345-361.
36. Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a meta-analysis. Br J Cancer 2003; 88: 1047-1053.
37. Brekelmans CT, Seynaeve C, Bartels CC et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19: 924-930.
38. Scheuer L, Kauff N, Robson M et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-1268.
39. Tilanus-Linthorst M, Verhoog L, Obdeijn IM et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002; 102: 91-95.
40. Adem C, Reynolds C, Soderberg CL et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 2003; 97: 1-11.
41. Kollias J, Sibbering DM, Blamey RW et al. Screening women aged less than 50 years with a family history of breast cancer. EJC 1998; 34: 878-883.
42. Kuhl CK, Schrading S, Leutner CC et al. Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: first mid-term results of a multi-modality clinical screening trial. J Clin Oncol 2003; 21: 238S.
43. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-1325.
44. Irwig L, Houssami N, van Vliet C. New technologies in screening for breast cancer: a systematic review of their accuracy. Br J Cancer 2004; 90: 2118-2122.
45. Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer 2002; 9: 141-153.
46. Heywang-Kobrunner SH, Viehweg P, Heinig A, Kuchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 1997; 24: 94-108.
47. Kneeshaw PJ, Turnbull LW, Drew PJ. Current applications and future direction of MR mammography. Br J Cancer 2003; 88: 4-10.
48. Morris EA. Review of breast MRI: indications and limitations. Semin Roentgenol 2001; 36: 226-237.
49. Neubauer H, Li M, Kuehne-Heid R, Schneider A, Kaiser WA. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol 2003; 76: 3-12.
50. Boetes C, Veltman J, van Die L, Bull P, Wobbes T, Barentsz JO. The role of MRI in invasive lobular carcinoma. Breast Cancer Res Treat 2004; 86: 31-37.
51. Rodenko GN, Harms SE, Pruneda JM et al. MR imaging in the management before surgery of lobular carcinoma of the breast: correlation with pathology. AJR Am J Roentgenol 1996; 167: 1415-1419.
52. Gilles R, Guinebretiere JM, Lucidarme O et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 1994; 191: 625-631.
53. Berg WA, Gutierrez L, NessAiver MS et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004; 233: 830-849.
54. Teifke A, Hlawatsch A, Beier T et al. Undetected malignancies of the breast: dynamic contrast-enhanced MR imaging at 1.0 T. Radiology 2002; 224: 881-888.
55. Kuhl GK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267-279.
56. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
57. MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-1778.
58. Duffy SW, Tabar L, Vitak B et al. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. EJC 2003; 39: 1755-1760.
59. Ikeda DM, Hylton NM, Kinkel K et al. Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging 2001; 13: 889-895.
60. Lo LD, Orel SG, Schnall MD. MR imaging-guided interventions in the breast. Magn Reson Imaging Clin N Am 2001; 9: 373-380, vii.
61. Kuhl CK, Bieling HB, Gieseke J et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203: 137-144.
62. van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95: 971-980.
63. Rijnshurger AJ, Essink-Bot ML, van Dooren S et al. Impact of screening for breast cancer in high-risk women on health-related quality of life. Br J Cancer 2004; 91: 69-76.
64. Warner E. Intensive radiologic surveillance: a focus on the psychological issues. Ann Oncol 2004; 15(Suppl. 1): 143-147.
65. van Dooren S, Seynaeve G, Rijnsburger AJ et al. Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer. Eur J Cancer 2005, in press.
66. van Dooren S, Seynaeve G, Rijnsburger AJ et al. The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer. Breast Cancer Res Treat 2005; 89: 75-80.
67. van Dooren S, Rijnsburger AJ, Seynaeve C et al. Psychological distress in women at increased risk for breast cancer: the role of risk perception. Eur J Cancer 2004; 40: 2056-2063.
68. van Dooren S, Rijnsburger AJ, Seynaeve G et al. Psychological distress and breast self-examination frequency in women at increased risk for hereditary or familial breast cancer. Community Genet 2003; 6: 235-241.
69. Watson EK, Henderson BJ, Brett J, Bankhead G, Austoker J. The psychological impact of mammographic screening on women with a family history of breast cancer-a systematic review. Psychooncology 2005, in press.
70. Saetersdal A, Dorum A, Heimdal K et al. Inherited predisposition to breast carcinoma. Results of first round examination of 537 women at risk. Anticancer Res 1996; 16: 1989-1992.
71. Moller P, Maehle L, Heimdal K et al. Inherited breast carcinoma. Prospective findings in 1194 women at risk. Acta Oncol 1996; 8: 7-11.
72. Chart PL, Franssen E. Management of women at increased risk for breast cancer preliminary results from a new program. Can Med Assoc J 1997; 157: 1235-1242.
73. Lalloo F, Boggis CRM, Evans DGR, Shenton A, Threlfall A, Howell A. Screening by mammography, women with a family history of breast cancer. EJC 1998; 34: 937-940.
74. Lai MS, Yen MF, Kuo HS, Koong SL, Chen THH, Duffy SW. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). IJC 1998; 78: 21-26.
75. Macmillan RD. Screening women with a family history of breast cancer - results from the British Familial Breast Cancer Group. Eur J Surg Oncol 2000; 26: 149-152.
76. Vasen HF, Tesfay E, Boonstra H et al. Early detection of breast and ovarian cancer in families with BRCA mutations. EJC 2005; 41: 549-554.
77. Tilanus-Linthorst MM, Ohdeijn IM, Bartels KC, De Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63: 53-60.
78. Stoutjesdijk MJ, Boetes C, Jager GJ et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-1102.
79. Podo F, Sardanelli F, Canese R et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21: 115-124.
80. Morris EA, Liberman L, Ballon DJ et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181: 619-626.
81. Hartman AR, Daniel BL, Kurian AW et al. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer 2004; 100: 479-489.
82. Lehman CD, Blume JD, Weatherall P et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103: 1898-1905.